Anti-Coagulants - Eastern Africa

Eastern Africa

The Anti-Coagulants market in Eastern Africa is expected to witness a significant growth in revenue, with projections reaching US$53.67m in 2024.
This positive trend is anticipated to continue, as the market is predicted to experience an annual growth rate (CAGR 2024-2029) of 7.95%.
By 2029, the market volume is estimated to reach US$78.67m.
When compared globally, it is worth noting that United States is expected to generate the highest revenue in the Anti-Coagulants market.
In 2024, United States is projected to generate a revenue of US$16,740.00m.
Eastern Africa is experiencing a growing demand for anti-coagulants due to an increasing prevalence of cardiovascular diseases in the region.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Eastern Africa has seen a steady growth in recent years.

Customer preferences: Patients in Eastern Africa are increasingly opting for Anti-Coagulants due to the rise in cardiovascular diseases and stroke cases in the region. Additionally, the convenience of oral anti-coagulants over traditional injectable anti-coagulants is driving the demand for these drugs.

Trends in the market: In Kenya, the Anti-Coagulants market is dominated by the vitamin K antagonist (VKA) drug class, but there is a shift towards direct oral anti-coagulants (DOACs) due to their ease of use and lower risk of bleeding. Tanzania is also seeing a similar trend, with an increasing preference for DOACs over VKAs. In Ethiopia, the Anti-Coagulants market is still in its nascent stages, but is expected to grow due to the rising prevalence of cardiovascular diseases in the country.

Local special circumstances: The healthcare infrastructure in Eastern Africa is still developing, leading to challenges in access to healthcare services and medication. Additionally, the high cost of Anti-Coagulants is a major barrier for patients in the region, as most of the drugs are imported.

Underlying macroeconomic factors: The economic growth in Eastern Africa has led to an increase in healthcare spending, which is expected to drive the growth of the Anti-Coagulants market. However, the region is still facing challenges such as poor healthcare infrastructure, low healthcare literacy, and a lack of funding for healthcare, which could hinder the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.